Ares Life Sciences, a Switzerland-based healthcare investment firm, must launch a takeover bid for Stallergenes, after acquiring 45.86% of the French allergy-specialist from Wendel, a French investment firm, for €59 per share. Wendel will receive around €358.8 million from Ares and is expected to declare a capital gain of around €300 million. Ares has told Stallergenes that it does not foresee any change within Stallergenes' jobs, salary or human resources policies.
Under French law, Ares must file a tender offer for all the remaining outstanding shares of Stallergenes - held either...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
